Search Results

Thomas P. Sakmar About Dr. Thomas P. Sakmar Tom Sakmar is a physician-scientist and professor at Rockefeller University in New York. dynamics simulations and coarse-grain sampling approaches for membrane proteins in collaborations with Thomas Thomas P. Sakmar on the web LinkedIn ResearchGate Pubmed ORCHID Google Scholar Rockefeller University Wikipedia

Thomas Sakmar’s laboratory at Rockefeller University, where she studies the signaling and degradation started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at Rockefeller University.

Thomas Sakmar’s laboratory at The Rockefeller University, where she study’s the signaling and degradation started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at The Rockefeller University.

Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .

, 53% had the extramedullary disease (EMD) at relapse, associated with dismal post-relapse outcome (P talquetamab, 64% and 32% for teclistamab, 30% and 0% for IMiDs/PIs/CD38, and 26% and 3% for others (P Duration of response, as well as median survival, was significantly improved with bispecific antibodies (P Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas

Kristina Sterner , Susanne Schinke , Nadja Käding , Jens Y Humrich , Otávio Cabral-Marques , Joana P Bernardes , Neha Mishra , Thomas Bahmer , Jeanette Franzenburg , Bimba F Hoyer , Andreas Glück , Martina

Meghana S Pagadala , Lauren M Clubb , Joshua Chiou , Sanju Sinha , Marin Matic , Francesco Raimondi , Thomas Rebecca Berdeaux , Dario A A Vignali , Ramiro Iglesias-Bartolome , Hannah Carter , Eytan Ruppin , Jill P

higher in the case group as compared to the control group (positivity 40.31 ± 3.01 vs. 20.46 ± 1.93, p < 0.001; density 2.77 ± 1.17 vs. 1.28 ± 0.37, p < 0.001). mRNA level was also upregulated in patients compared to the controls (2.36 ± 1.30 vs. 1.09 ± 0.42, p < 0.001) and showed a positive correlation with immunostaining of protein in OSCC (r = 0.48, p = 0.011 differentiation (p = 0.013), clinical TNM stages (p = 0.014), and poor survival (p = 0.006) of patients

Ilana Kotliar "Ilana Kotliar is a postdoctoral associate in the lab of Tom Sakmar at The Rockefeller

Low PAXIP1-AS1 expression in OC was associated with age (P = 0.045), histological grade (P = 0.011), and lymphatic invasion (P = 0.004). Low PAXIP1-AS1 expression predicted a poorer overall survival (OS) (HR: 0.71; 95% CI: 0.55-0.92; P = survival (DSS) (HR: 0.67; 95% CI: 0.51-0.89; P = 0.006). PAXIP1-AS1 expression (HR: 0.711; 95% CI: 0.542-0.934; P = 0.014) was independently correlated with PFS

He then moved to Thomas Jefferson University in Philadelphia, PA, for his postdoctoral training in Jeff

β1 AR) , M5-muscarinic (M5AR), and angiotensin II type 2 receptors (AT2R) were increased in HF (all P against α1 -adrenergic (α1 AR) and angiotensin II type 1 receptors (AT1R) were decreased in HF (all P < 0.05) and global longitudinal strain (r = -0.323, P < 0.05). In insulin-resistant HF patients, AT2R autoantibodies were decreased (r = -.240, P < 0.05), and AT1R autoantibodies were increased (r = 0.212, P < 0.05).

to promote the expressions of GPRC5A compared with those of the NC group (1.00±0.01, 1.00±0.00)(all P< increase of GPRC5A at both gene and protein levels induced by LPS (1.30±0.10, 1.43±0.03) (F=208.38, P< 0.001; F=42.04, P<0.001). PTGS2 at the gene level in LPS group were highly increased compared with those in the NC group (all P< in the NC group, and siGPRC5A could effectively suppressed LPS-induced protein phosphorylation (all P<

significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032 ) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb.

of evaluated autoantibodes were significantly higher in Long-COVID compared to the 2 other groups (p higher number of patients with simultaneous detection of more than one autoantibody in Long-COVID group (p ARB1 and ARB2 correlated negatively CERAD Trail Marking A and B (R ≤ -0.26, p ≤ 0.043), while CHRM3 correlated positively with Chadler Fatigue Scale (R = 0.37, p = 0.0087).

patients receiving CLAG-M/sorafenib at RP2D (OS: hazard ratio,0.24 [95% confidence interval, 0.07-0.82]; P = .023; EFS: hazard ratio, 0.16 [95% confidence interval, 0.05-0.53]; P = .003). Benefit was limited to patients with intermediate-risk disease (univariate analysis: P = .01 for OS; P = .02 for EFS).

However, Vibrio parahaemolyticus infection poses a major challenge in ensuring the success of P. vannamei conducted to identify the interaction sites and binding affinity between several immune-related proteins of P. The P. vannamei-V. parahaemolyticus protein-protein interaction of Complex 1 (Ferritin-HrpE/YscL family simulation analysis, which revealed these complexes greatly contribute to the interactions between P.

to the Vollum Institute in Portland, Oregon, to do a post-doctoral fellowship in the laboratory of Thomas

On multivariable analysis, hypogammaglobulinemia (hazard ratio [HR], 6.06; P = .044) and diagnosis of an early respiratory viral infection (HR, 2.95; P = .048) were independent risk factors for late respiratory Nadeem , Adam S Sperling , Noopur Raje , Nikhil Munshi , Matthew Frigault , Sara Barmettler , Sarah P

Thomas Südhof .

Authors Bikash Chandra Jena, Daniel P Flaherty, Valerie P O'Brien, Val J Watts Tags Adenylyl Cyclase

obesity Date & Time Friday, November 3rd / 2:45 PM Abstract Coming Soon Authors and Affiliations Ryan P. Ayala 5, Owen P. McGuinness 5, Sheila Collins 1,5, Heidi E.

Authors Kirti V Sawant , Krishna Mohan Sepuru , Brigith Penaranda , Emily Lowry , Roberto P Garofalo

Authors R Mishra, S K Biswas, S Nandi, S Mahajan, K G Sai Balaji, V Gairola, D Poloju, S Gulzar, K P

Shafiei-Jahani, Shi Yan, Mohammad H Kazemi, Xin Li, Amitis Akbari, Kei Sakano, Yoshihiro Sakano, Benjamin P

gamma-AS1 , Interferon regulatory factor 1 , Interferon-gamma , Interleukin , Interleukin-1 receptor alpha P Sialic-acid-binding immunoglobulin-like lectin 8 , Signal transducer and activator of transcription , Substance P

Authors Nick D Bergkamp , Jeffrey R van Senten , Hendrik J Brink , Maarten P Bebelman , Jelle van den

characteristics of growth hormone (GH)-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors (GHomas the genetic alterations, protein expression profiles, transcriptomes, and clinical characteristics of GHomas genes and nontargeted proteomics analysis were performed on fresh-frozen samples from 121 sporadic GHomas